Role of endothelin in human hypertension

Canadian Journal of Physiology and Pharmacology

Volumn 81, Issue 6, 2003, Pages 533-541

  Touyz, Rhian M ^a   Schiffrin, Ernesto L ^a  

^a CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

Author keywords

Endothelin ETA and ETB receptors; Endothelium; Essential hypertension; Vascular remodeling

Indexed keywords

ANGIOTENSIN; BRADYKININ; CYTOKINE; ENDOTHELIN; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; ENDOTHELIN B RECEPTOR ANTAGONIST; N ACETYLENDOTHELIN 1 [6-21][11,15 ALANINE]; NORADRENALIN; RENIN; SARAFOTOXIN S6A; THROMBIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASOACTIVE AGENT; VASOPRESSIN;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; ESSENTIAL HYPERTENSION; FIBROSIS; HEART FAILURE; HOMEOSTASIS; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOREACTIVITY; INFLAMMATION; INSULIN RESISTANCE; MECHANICAL STRESS; MITOGENESIS; OBESITY; PLEIOTROPY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; REVIEW; SIGNAL TRANSDUCTION; STRESS; VASOCONSTRICTION;

ANIMALS; ENDOTHELIN-1; HUMANS; HYPERTENSION; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B;

EID: 0038300784     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/y03-009     Document Type: Review

References (93)

1. Bacon, C.R., Cary, N.R., and Davenport, A.P. 1996. Endothelin peptide and receptors in human atherosclerotic coronary artery and aorta. Cir. Res. 79: 794-801.
2. Barden, A., Beilin, L.J., Ritchie, J., Walters, B.N., and Michael, C.A. 1994. Plasma and urinary endothelin-1, prostacyclin metabolites and platelet consumption in pre-eclampsi and essential hypertensive preganancy. Blood Pressure, 3: 38-46.
3. Barden, A.E., Herbison, C.E., Beilin, L.J., Michael, C.A., Walters, B.N., and Van Bockxmeer, F.M. 2001. Association between the ET-1 gene Lys198Asn polymorphism blood pressure and plasma ET-1 levels in normal and pre-eclamptic pregnancy. J. Hypertens. 19: 1775-1782.
4. Bobik, A., Grooms, A., Millar, J.A., Mitchell, A., and Grinpukel, S. 1990. Growth factor activity of endothelin on vascular smooth muscle. Am. J. Physiol. (Cell Physiol.), 258: C408-C415.
5. Bragulat, E., de la Sierra, A., Antonio, M.T., Jimenez, W., Urbano-Marquez, A., and Coca, A. 2001. Endothelial dysfunction in salt-sensitive essential hypertension. Hypertension (Dallas), 37: 444-448.
6. Cardillo, C., Kilcoyne, C.M., Waclawiw, M., Cannon, R.O., III, and Panza, J.A. 1999. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension (Dallas), 33: 753-758.
7. Carlini, R., Obialo, C.I., and Rothstein, M. 1993. Intravenous erythropoietin (rHuEPO) administration increases plasma endothelin and blood pressure in hemodialysis patients. Am. J. Hypertens. 6: 103-107.
8. Channick, R.N., Simonneau, G., Sitbon, O., Robbins, I.M., Frost, A., Tapson, V.F., Badesch, D.B., Roux, S., Rainisio, M., Bodin, F., and Rubin, L.J. 2001. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet, 358(6): 1119-1123.
9. Clarke, B.A., Halvorson, L., Sachs, B., and Epstein, F. 1992. Plasma endothelin levels in pre-eclampsia: elevation and correlation with uric acid levels and renal impairment. Am. J. Obstet. Gynecol. 166: 962-968.
10. Cuzzola, F., Mallamaci, F., Tripepi, G., Parlongo, S., Cutrupi, S., Cataliotti, A., Stancanelli, B., Malatino, L., Bellanuova, I., Ferri, C., Galletti, F., Filigheddu, F., Glorioso, N., Strazzullo, P., and Zoccali., C. 2001. Urinary adrenomedullin is related to ET-1 and salt intake in patients with mild essential hypertension. Am. J. Hypertens. 14: 224-230.
11. Dupuis, J. 2000. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics. Can. J. Cardiol. 16(7): 903-910.
12. D'Uscio, L.V., Barton, M., Shaw, S., Moreau, P., and Lüscher, T.F. 1997. Structure and function of small arteries in salt-induced hypertension - effects of chronic endothelin-subtype-A-receptor blockade. Hypertension (Dallas), 30: 905-911.
13. Elijovich, F., Laffer, C.L., Gavras, H., Bresnahan, M.R., and Schiffrin, E.L. 2001. Regulation of plasma endothelin by salt in salt-sensitive hypertension. Circulation, 103: 263-268.
14. Ergul, A. 2000. Hypertension in black patients. An emerging role of the endothelin system in salt-sensitive hypertension. Hypertension (Dallas), 36: 62-67.
15. Ergul, S., Parish, D.C., Puett, D., and Ergul, A. 1996. Racial differences in plasma endothelin-1 concentrations in individuals with essential hypertension. Hypertension (Dallas), 28: 652-655.
16. Ergul, A., Tackett, R.L., and Puett, D. 1999. Distribution of endothelin receptors in saphenous vein of African Americans: implications of racial differences. J. Cardiovasc. Pharmacol. 34: 327-332.
17. Ergul, S., Ergul, A., Hudson, J.A., Puett, D., Wieman, B.M., Durham, M.D., and Parish, D.C. 1998. The effect of regulation of high blood pressure on plasma ET-1 levels in blacks with hypertension. Am. J. Hypertens. 11: 1381-1385.
18. Ferri, C., Bellini, C., and Desideri, G. 1997. Elevated plasma and urinary endothelin-1 levels in human salt-sensitive hypertension. Clin. Sci. 93: 35-41.
19. Ferri, C., Bellini, C., Desideri, G., Giuliani, E., De Siati, L., Cicogna, S., and Santucci, A. 1998. Clustering of endothelial markers of vascular damage in human salt-sensitive hypertension: influence of dietary sodium load and depletion. Hypertension (Dallas), 32: 862-868.
20. Goddard, J., and Webb, D.J. 2000. Plasma endothelin concentrations in hypertension. J Cardiovasc. Pharmacol. 35(4): S25-S31.
21. Greer, I.A., Leask, R., Hodson, B.A., Dawes, J., Kilpatrick, D.C., and Liston, W.A. 1991. Endothelin, elastase, and endothelial dysfunction in pre-eclampsia. Lancet, 337: 558.
22. Guvener, N., Aytemir, K., Aksoyek, S., and Gedik, O. 1997. Plasma endothelin-1 levels in non-insulin dependent diabetes mellitus patients with macrovascular disease. Coron. Artery Dis. 8: 253-258.
23. Haak, T., Jungmann, E., Felber, A., Hillman, U., and Usadel, K.H. 1992. Increased plasma levels of endothelin in diabetic patients with hypertension. Am. J. Hypertens. 5: 161-166.
24. Haak, T., Marz, W., Jungmann, E., Hausser, S., Siekmeier, R., Gross, W., and Usadel, K.H. 1994a. Elevated endothelin levels in patients with hyperlipoproteinemia. Clin. Investig. 72: 580-584.
25. Haak, T., Jungmann, E., Raab, C., and Usadel, K.H. 1994b. Elevated endothelin-1 levels after cigarette smoking. Metab. Clin. Exp. 43: 267-269.
26. A receptor and is comitogenic with growth factors. Atherosclerosis, 146: 351-359.
27. Hasdai, D., and Lerman, A. 1995. The atherogenic potential of endothelin. Coron. Artery Dis. 6: 901-904.
28. Hasegawa, K., Fujiwara, H., Doyama, K., Inada, T., Ohtani, S., Fujiwara, T., Hosoda, K., Nakao, K., and Sasayama, S. 1994. Endothelin-1 selective receptor in the arterial intima of patients with hypertension. Hypertension (Dallas), 23: 288-293.
29. Haynes, W.G., and Webb, D.J. 1998. Endothelin as a regulator of cardiovascular function in health and disease. J. Hypertens. 16: 1081-1098.
30. Haynes, W.G., Hand, M.F., Johnstone, H.A., Padfield, P.L., and Webb, D.J. 1994. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin- 1. J. Clin. Investig. 94: 1359-1364.
31. Haynes, W.G., Ferro, C.J., and O'Kane, K.P. 1996. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blood pressure in humans. Circulation, 93: 1860-1870.
32. Hirata, Y., Takagi, Y., Fukuda, Y., and Marumo, F. 1989. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis, 78: 225-228.
33. Hoffman, A., Grossman, E., and Goldstein, D.S. 1994. Urinary excretion rate of endothelin-1 in patients with essential hypertension and salt sensitivity. Kidney Int. 45: 556-560.
34. Hopfner, R.L., and Gopalakrishnan, V. 1999. Endothelin: emerging role in diabetic vascular complications. Diabetologia, 42: 1383-1394.
35. Hwang, Y.S., Hsieh, T.J., Lee, Y.J., and Tsai, J.H. 1998. Circadian rhythm of urinary endothelin-1 excretion in mild hypertensive patients. Am. J. Hypertens. 11: 1344-1351.
36. Inoue, A., Yanagisawa, M., Kimura, S., Kasuya, Y., and Miyauchi, T. 1989. The human endothelin family-3 structurally and pharmacologically distinct isopeptides predicted by 3 separate genes. Proc. Natl. Acad. Sci. U.S.A. 86: 2863-2867.
37. Kanno, K., Hirata, Y., Shichiri, M., and Marumo, F. 1991. Plasma endothelin-1 levels in patients with diabetes mellitus with or without vascular complications. J. Cardiovasc. Pharmacol. 17: S475-S476.
38. Khan, Z.A., and Chakrabarti, S. 2003. Endothelins in chronic diabetic complications. Can. J. Physiol. Pharmacol. 81. This issue.
39. Kohno, M., Yasumari, K., Murakawa, K., Yokokawa, K., Horio, T., Fukui, T., and Takeda, T. 1990. Plasma immunoreactive endothelin in essential hypertension. Am. J. Med. 88: 614-618.
40. Krum, H., Viskoper, R.J., Lacourciere, Y., Budde, M., and Charlon, V. 1998. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N. Engl. J. Med. 338: 784-790.
41. Krum, H., Denver, R., Tzanidis, A., and Martin, P. 2001. Diagnostic and therapeutic potential of the endothelin system in patients with chronic heart failure. Heart Failure Rev. 6(4): 341-352.
42. Larivière, R., Thibault, G., and Schiffrin, E.L. 1993a. Increased endothelin-1 content in blood vessels of deoxycorticosterone acetate-salt hypertensive but not in spontaneously hypertensive rats. Hypertension (Dallas), 21: 294-300.
43. Larivière, R., Day, R., and Schiffrin, E.L. 1993b. Increased expression of endothelin-1 gene in blood vessels of deoxycorticosterone acetate-salt hypertensive rats. Hypertension, 21: 916-920.
44. Lerman, A., Edwards, B.S., Hallet, J.W., Heulbein, D.M., Sandberg, S.M., and Burnett, J.C., Jr. 1991. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N. Engl. J. Med. 325: 997-1001.
45. Lerman, A., Holmes, D.R., Bell, M.R., Garrat, K.N., Nishimura, R.A., and Burnett, J.C., Jr. 1995. Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. Circulation, 92: 2426-2431.
46. Letizia, C., Cerci, S., and De Toma, G. 1997. High plasma endothelin-1 levels in hypertensive patients with low-renin essential hypertension. J. Hum. Hypertens. 11: 447-451.
47. Malatino, L.S., Bellanuova, I., Cataliotti, A., Cuzzola, F., Mallamaci, F., Tripepi, G., Parlongo, S., Cutrupi, S., Mangiafico, R.A., Ferri, C., Galletti, F., Glorioso, N., Strazzullo, P., and Zoccali, C. 2000. Renal endothelin-1 is linked to changes in urinary salt and volume in essential hypertension. J Nephrol. 13: 178-184.
48. Malamitsi-Puchner, A., Economou, E., Katsouyanni, K., Karachaliou, F., Delis, D., and Bartsocas, C.S. 1996. Endothelin 1-21 plasma concentrations in children and adolescents with insulin dependent diabetes mellitus. J. Pediatr. Endocrinol. Metab. 9: 463-468.
49. Marano, G., Grigioni, M., Palazzesi, S., and Ferrari, A.U. 1999. Endothelin and mechanical properties of the carotid artery in Wistar-Kyoto and spontaneously hypertensive rats. Cardiovasc. Res. 41: 701-707.
50. Nugent, A.G., McGurk, C., Hayes, J.R., and Johnston, G.D. 1996. Impaired vasoconstriction to endothelin-1 in patients with NIDDM. Diabetes, 45: 105-107.
51. A antagonist prevents blood pressure elevation and vascular hypertrophy of resistance arteries in aldosterone-infused rats. Hypertension (Dallas), 37: 1444-1449.
52. Parrinello, G., Scaglione, R., and Pinto, A. 1996. Central obesity and hypertension: the role of plasma endothelin. Am. J. Hypertens. 9: 1186-1191.
53. Perfetto, F., Tarquini, R., and de Leonardis, V. 1997. Vascular damage and not hypertension per se influences endothelin-1 plasma levels in patients with non-insulin dependent diabetes mellitus. Recenti Prog. Med. 88: 317-320.
54. Phillips, P.A., Rolls, K.A., Burrell, L.M., Casley, D., Aldred, K.L., Hardy, K.J. 1994. Vascular endothelin responsiveness and receptor characteristics in vitro and effects of endothelin receptor blockade in vivo in cyclosporin hypertension. Clin. Exp. Pharmacol. Physiol. 21: 223-226.
55. Phillips, B.G., Narkiewicz, K., Pesek, C.A., Haynes, W.G., Dyken, M.E., and Somers, V.K. 1999. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J. Hypertens. 17: 61-66.
56. Rossi, G.P., Colonna, S., Pavan, E., Albertin, G., Della, R., Gerosa, G., Casarotto, D., Sartore, S., Pauletto, P., and Pessina, A.C. 1999. Endothelin-1 and its mRNA in the wall layers of human arteries ex vivo. Circulation, 99: 1147-1155.
57. Roullet, J.B., Xue, H., McCarron, D.A., Holcomb, S., and Bennett, W.M. 1994. Vascular mechanisms of cyclosporin-induced hypertension in the rat. J. Clin. Investig. 93: 2244-2250.
58. Rubanyi, G.M., and Polokoff, M.A. 1994. Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. 46: 325-415.
59. Russell, F.D., Skepper, J.N., and Davenport, A.P. 1997. Detection of endothelin receptors in human coronary artery vascular smooth muscle cells but not endothelial cells by using electron microscope autoradiography. J. Cardiovasc. Pharmacol. 29: 820-826.
60. Saito, Y., Nakao, K., and Mukoyama, M. 1990. Increased plasma endothelin level in patients with essential hypertension. N. Engl. J. Med. 322: 205.
61. Saito, I., Mizuno, K., and Niimura, S. 1993. Urinary endothelin and sodium excretion in essential hypertension. Nephron, 65: 152-153.
62. Schiffrin, E.L. 1995. Endothelin: potential role in hypertension and vascular hypertrophy. Hypertension (Dallas), 25: 1135-1143.
63. Schiffrin, E.L. 2001. Role of endothelin-1 in hypertension and vascular disease. Am. J. Hypertens. 14: 83S-89S.
64. Schiffrin, E.L., and Thibault, G. 1991. Plasma endothelin in human essential hypertension. Am. J. Hypertens. 4: 303-308.
65. Schiffrin, E.L., Deng, L.Y., and Larochelle, P. 1992. Blunted effects of endothelin upon small subcutaneous resistance arteries of mild essential hypertensive patients. J. Hypertens. 10: 437-444.
66. Schiffrin, E.L., Larivière, R., Li, J.S., Sventek, P., and Touyz, R.M. 1995. Deoxycorticosterone acetate plus salt induces overexpression of vascular endothelin-1 and severe vascular hypertrophy in spontaneously hypertensive rats. Hypertension (Dallas), 25(Part 2): 769-773.
67. Schiffrin, E.L., Deng, L.Y., Sventek, P., and Day, R. 1997a. Enhanced expression of endothelin-1 gene in endothelium of resistance arteries in severe human essential hypertension. J. Hypertens. 15: 57-63.
68. Schiffrin, E.L., Intengan, H.D., Thibault, G., and Touyz, R.M. 1997b. Clinical significance of endothelin in cardiovascular disease. Curr. Opin. Cardiol. 12: 354-367.
69. Schneider, M.P., Hilgers, K.F., Klingbeil, A.U., Johns, S., Veelken, R., and Schmieder, R.E. 2000. Plasma ET-1 is increased early in hypertension. Am. J. Hypertens. 13(6): 579-585.
70. Shaarawy, M., and Abdel-Magid, A.M. 2000. Plasma ET-1 and mean arterial pressure in the prediction of preeclampsia. Int. J. Gynaecol. Obstet. 68(20): 105-111.
71. Shichiri, M., Hirata, Y., and Ando, K. 1990. Plasma endothelin levels in hypertension and chronic renal failure. Hypertension (Dallas), 15: 493-496.
72. Singh, H.J., Rahman, A., Larmie, E.T., and Nila, A. 2001. ET-1 in feto-placental tissues from normotensive pregnant women and women with pre-eclampsia. Acta Obstet. Gynecol. Scand. 80(2): 99-103.
73. Smulders, R.A., Stehouwer, C.D., and Olthof, C.G. 1994. Plasma endothelin levels and vascular effects of intravenous L-arginine in subjects with uncomplicated insulin-dependent diabetes mellitus. Clin. Sci. 87: 37-43.
74. A receptor antagonism with BQ-123 blocks ET-1 induced forearm vasoconstriction and decreases peripheral vascular resistance in healthy men. Br. J. Pharmacol. 134: 648-654.
75. Stockenhuber, F., Gottsauner-Wolf, M., Marosi, L., Liebisch, B., Kurz, R.W., and Balcke, P. 1992. Plasma levels of endothelin in chronic renal failure and after renal transplantation: impact on hypertension and cyclosporin A-associated nephrotoxicity. Clin. Sci. 82: 255-258.
76. Strachan, F.E., Spratt, J.C., Wilkinson, I.B., Johnston, N.R., Gray, G.A., and Webb, D.J. 1999. Systemic blockade of the endothelin-B receptor increases peripheral vascular resistance in healthy men. Hypertension (Dallas), 33: 581-585.
77. Sventek, P., Turgeon, A., Garcia, R., and Schiffrin, E.L. 1996. Vascular and cardiac overexpression of endothelin-1 gene in one-kidney one clip Goldblatt hypertensive rats but only in the late phase of two-kidney one clip Goldblatt hypertension. J. Hypertens. 14: 57-64.
78. Taddei, S., Virdis, A., Ghiadoni, L., Sudano, I., Notari, M., and Salvetti, A. 1999. Vasoconstriction to endogenous ET-1 is increased in the peripheral circulation of patients with essential hypertension. Circulation, 100(16): 1680-1683.
79. Takahashi, K., Totsune, K., and Mouri, T. 1994. Endothelin in chronic renal failure. Nephron, 66(4): 373-379.
80. Tarquini, B., Perfetto, F., Tarquini, R., Cornelissen, G., and Halberg, F. 1997. Endothelin-1's chronome indicates diabetic and vascular disease chronorisk. Peptides (N.Y.), 18(1):119-132.
81. Thorin, E., Parent, R., Ming, Z., and and Lavallee, X.X. 1999. Contribution of endogenous endothelin to large epicardial coronary artery tone in dogs and humans. Am. J. Physiol. 277: H524-H532.
82. Touyz, R.M., Turgeon, A., and Schiffrin, E.L. 2000. Endothelin A receptor blockade improves renal function and doubles the lifespan of stroke-prone hypertensive rats. J. Cardiovasc. Pharmacol. 36(1): S300-S304.
83. Uemasu, J., Munemura, C., Fujihara, M., and Kawasaki, H. 1994. Inhibition of plasma endothelin-1 concentration by captopril in patients with essential hypertension. Clin. Nephrol. 41: 150-152.
84. Verhaar, M.C., Strachan, F.E., and Newby, D.E. 1998. Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-B receptor blockade. Circulation, 97: 752-756.
85. A selective endothelin antagonist, in humans. Br. J. Clin. Pharmacol. 49(6): 562-573.
86. Wagner, O.F., Christ, G., and Wojta, J. 1992. Polar secretion of endothlin-1 by cultured endothelial cells. J. Biol. Chem. 267: 16 066-16 068.
87. Webb, D.J., Monge, J.C., and Rabelink, T.J. 1998. Endothelin: new discoveries and rapid progress in the clinic. Trends Pharmacol. Sci. 19: 5-8.
88. Wenzel, R.R., Noll, G., and Luscher, TF. 1994. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension (Dallas), 23: 581-586.
89. Wenzel, R.R., Ruthermann, J., Bruck, H., Schafers, R.F., Michel, M.A., and Philipp, T. 2001. Endothelin-A receptor antagonist inhibits angiotensin II and noradrenaline in man. Br. J. Clin Pharmacol. 52: 151-157.
90. Williamson, D.J., Wallman, L.L., and Jones, R. 2000. Hemodynamic effects of bosentan an endothelin receptor antagonist in patients with pulmonary hypertension. Circulation, 102: 411-418.
91. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London), 332: 411-415.
92. Zaporowska-Stachowiak, I., Gluszek, J., and Chodera, A. 1997. Comparison of the serum insulin and endothelin level in patients with essential and renovascular hypertension. J. Hum. Hypertens. 11: 795-800.
93. Zoccali, C., Leonardis, D., Parlongo, S., Mallamaci, F., and Postorino, M. 1995. Urinary and plasma endothelin 1 in essential hypertension and in hypertension secondary to renoparenchymal disease. Nephrol. Dial. Transplant. 10: 1320-1323.